AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...

Natural products industry companies share overviews on the latest science on their dietary supplement branded ingredients and ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the key takeaways from the ASCO 2025 Annual ...

The ADA Scientific Sessions is a globally recognized conference dedicated to advancing the field of diabetes. This annual meeting serves as a critical forum for presenting cutting-edge research, ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of growth & business development, DIA, reflects on the importance of leadership ...

On April 26, 2025, Dr. Sarah Ronis, a Clinical & Translational Science (CTS) Research Program awardee and recent Co-Investigator on a 2024 Annual Pilot award with the Clinical and Translational ...

Session Type: E-Poster Poster No.: 145eTiP About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.

Presentation Details: Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle stimulating hormone receptor (FSHR) in recurrent ...